Chumpower Machinery Corporation logo

Chumpower Machinery Corporation (4575)

Market Closed
11 Aug, 05:30
TWSE TWSE
JPX JPX Primary
TWSE TWSE
NT$
23. 65
+1.4
+6.2921%
NT$
- Market Cap
- P/E Ratio
- Div Yield
16,005 Volume
- Eps
NT$ 22.25
Previous Close
Add Transaction
Day Range
22.9 23.65
Year Range
19.7 41.15
Want to track 4575 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

4575 closed today higher at NT$23.65, an increase of 6.2921% from yesterday's close, completing a monthly decrease of -8.8632% or -NT$2.3. Over the past 12 months, 4575 stock gained 13.7019%.
4575 pays dividends to its shareholders, with the most recent payment made on May 22, 2026. The next estimated payment will be in In 9 months on May 22, 2027 for a total of NT$1.3.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Chumpower Machinery Corporation has completed 1 stock splits, with the recent split occurring on Sep 03, 2019.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on JPX (JPY).

4575 Chart

No Data

Chumpower Machinery Corporation (4575) FAQ

What is the stock price today?

The current price is NT$23.65.

On which exchange is it traded?

Chumpower Machinery Corporation is listed on TWSE.

What is its stock symbol?

The ticker symbol is 4575.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Chumpower Machinery Corporation ever had a stock split?

Chumpower Machinery Corporation had 1 splits and the recent split was on Sep 03, 2019.

Chumpower Machinery Corporation Profile

Biotechnology Industry
Healthcare Sector
Mr. Takumi Kawabe M.D., Ph.D. CEO
TWSE Exchange
TW0004575006 ISIN
Japan Country
14 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

CanBas Co., Ltd. is a clinical stage biopharmaceutical company focused on developing innovative therapeutics for cancer patients. Established in 2000, the company has positioned itself in the bio-pharmaceutical industry with a dedication to research and development, manifesting in its pioneering work on calmodulin-modulating peptides and reversible exportin-1 inhibitors. Based in Numazu, Japan, it has established a significant collaboration alliance with Stemline Therapeutics, Inc., broadening its research and market reach. CanBas is committed to advancing cancer treatment methodologies through scientific innovation and strategic partnerships.

Products and Services

  • CBP501

    • A calmodulin-modulating peptide developed by CanBas, CBP501, represents a therapeutic innovation aimed at targeting various cancers. It embodies the company's focus on groundbreaking cancer treatment solutions, leveraging biological mechanisms for effective disease management.

  • CBS9106

    • As a reversible exportin-1 inhibitor currently in Phase I clinical trial, CBS9106 is a testament to CanBas's commitment to exploring new frontiers in cancer treatment. Aimed at treating solid tumors, this product signifies a promising step forward in the fight against cancer through the inhibition of nuclear export signals.

Contact Information

Address: 2-2-1, Otemachi
Phone: 81 55 954 3666
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark